Clinical trials: Anticoagulant-induced Bleeding, open to volunteers
Sarcoma, Soft Tissue Sarcoma
LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
Aspirin and low molecular weight heparin (LMWH) are both commonly employed pharmacologic methods of venous thromboembolism (VTE) prophylaxis after orthopaedic surgery.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases
- Trial name
- NCT03244020
- Testing
- Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe
- Where
- 10 sites in United States
- Volunteers
- 2,868 people
- Sponsor
- Massachusetts General Hospital
Anticoagulant-induced Bleeding, Direct Oral Anticoagulant
Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation Pilot Study
The peri-procedural management of direct oral anticoagulants (DOACs) in persons with cancer (PWC) undergoing tunneled or port central venous catheter (CVC) insertion is a common but understudied clinical problem, with conflicting…
- Conditions
- Anticoagulant-induced Bleeding, Direct Oral Anticoagulant, Cancer, Central Venous Catheter
- Trial name
- VENO CAT (NCT06887270)
- Testing
- Continued DOAC, Interrupted DOAC
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Pulmonary Embolism, Embolism
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
The clinical significance of pulmonary embolism (PE) limited to the subsegmental pulmonary arteries, so called isolated subsegmental pulmonary embolism (SSPE), remains controversial.
- Conditions
- Pulmonary Embolism, Embolism, Embolism and Thrombosis, Lung Diseases
- Trial name
- SAFE-SSPE (NCT04263038)
- Testing
- Rivaroxaban
- Where
- 40 sites in Belgium, Canada and 3 more
- Volunteers
- 276 people
- Sponsor
- Drahomir Aujesky
Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB)
FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)
Background Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended for stroke prevention in non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB), Gastrointestinal Hemorrhage (Clinically Important, Upper), Drug-Related Side Effects and Adverse Reactions
- Trial name
- FENOX (NCT07497893)
- Testing
- Fexuprazan, NOAC therapy
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Ewha Womans University Mokdong Hospital
GastroIntestinal Bleeding, Anticoagulant-induced Bleeding
Anticoagulation After GI Bleeding Pilot Study and Registry
PANTHER-GI Pilot Study will assess the feasibility of a full-scale multicentre cohort management study evaluating the safety of a standardized strategy for resuming direct oral anticoagulants (DOACs) after major DOAC-related…
- Trial name
- PANTHER-GI (NCT05290857)
- Testing
- Restart DOAC within 7 days of clinical hemostasis after GI bleeding, Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Hospital Research Institute